Kamran Riaz to Clinical Trials, Phase I as Topic
This is a "connection" page, showing publications Kamran Riaz has written about Clinical Trials, Phase I as Topic.
Connection Strength
0.046
-
Reversible HER2 antibody-drug conjugate-induced ocular toxicity. Can J Ophthalmol. 2022 04; 57(2):118-126.
Score: 0.046
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.